Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact: Study coordinator (YANG YANG, M.D.) · yangyang@zjcc.org.cn · +8657188128182
Contact: Principal Investigator (Youhua Jiang)
Contact: Principal Investigator (Guoqin Qiu)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.

Metastatic Esophageal Squamous Cell Carcinoma

Abroad (travel likely)Recruiting

Shanghai, China

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Squamous Non-small-cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Scottsdale, United States · Fullerton, United States

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China